CHAD Therapeutics Receives FDA Clearance to Market Its Newest Oxygen Conserving Device.CHATSWORTH, Calif. -- CHAD Therapeutics, Inc. (AMEX AMEX See: American Stock Exchange :CTU CTU Colorado Technical University CTU Czech Technical University in Prague CTU Counter Terrorist Unit CTU Clinical Trials Unit CTU Catholic Theological Union CTU Chicago Teachers Union CTU Computer Training Unit CTU Control Unit ) announced today that it has received clearance from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to market its new LOTUS(TM) Electronic Oxygen Conserver. The latest addition to CHAD's extensive line of oxygen conserving devices, the new LOTUS conserver combines innovative new features with the proven technologies in the company's OXYMATIC(R) 400 series conservers. "The LOTUS conserver offers several significant enhancements to our popular OXYMATIC 400 series platform. Sleek and lightweight at less than a pound, our new device will be offered with or without a breath-sensing alarm, and will incorporate additional liter flow settings and an audible and visual low battery alarm. Two AA-size batteries will provide power for up to four months of normal usage. An optional rechargeable battery A rechargeable battery, also known as a storage battery, is a group of two or more secondary cells. These batteries can be restored to full charge by the application of electrical energy. pack will also be available for both versions," said Earl Yager, President and Chief Executive Officer. "The advanced features we developed for our new LOTUS conserver demonstrate yet again CHAD's commitment to offering homecare providers and their patients the widest array of home oxygen choices to suit individual needs, preferences and disease conditions. This is the cornerstone of our long-term growth strategy. The increasing popularity of our conservers is evidence that our strategy is working," Yager added. Yager said that CHAD will exhibit the LOTUS conserver at the Medtrade show in Orlando, Florida The city of Orlando is a major city in central Florida and is the county seat of Orange County, Florida. According to the 2000 census, the city population was 185,951. A 2006 U.S. from October 26 to 28, 2004, and currently plans to begin shipping this new product in December. About CHAD Therapeutics CHAD Therapeutics, Inc. is in the business of developing, producing and marketing respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases. For more information, visit www.CHADtherapeutics.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statements under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The foregoing statements regarding prospects for future earnings and revenues, future sales trends and the introduction of products under development are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve certain risks and uncertainties. A number of important factors could cause actual results to differ materially from those contemplated by such forward-looking statements. These include the loss of one or more major customers, increased competition, the introduction of new products with perceived competitive advantages over the Company's products, changes or proposed changes in health care reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. which affect home care providers and CHAD's ability to anticipate and respond to technological and economic changes in the home oxygen market. Moreover, the success of the Company's products and products under development will depend on their efficacy, reliability and the health care community's perception of the products' capabilities and benefits, the degree of acceptance the products achieve among homecare providers and, with respect to products under development, obtaining timely regulatory approval. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Company's annual and quarterly reports filed with the Securities and Exchange Commission under the caption "Outlook: Issues and Risks." |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion